NJ-CELGENE
17.12.2018 13:32:09 CET | Business Wire | Press release
Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world.
The programs selected are expected to support established institutions partnering with in-country medical centers that provide essential cancer care services including awareness and education, prevention, diagnosis and care. The Celgene Cancer Care Links program is an initiative of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world.
“Celgene Cancer Care Links is another program we have created to make a meaningful impact for patients and healthcare systems around the world,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We are excited to announce the first round of grants through this initiative and wish these world-renowned organizations and institutions great success.”
Recipients of Celgene Cancer Care Links grants include:
| Program Title | Organization | Partner Institution | |||||||
| Standard of care for pediatric Kaposi Sarcoma in Lilongwe, Malawi | Baylor College of Medicine, Texas Children’s Hospital, Houston, TX | Baylor College of Medicine Children’s Foundation – Malawi | |||||||
| National cervical cancer prevention program in Haiti: scaling up a pilot project | Basic Health International, New York, NY | St. Luke’s Foundation/Carmelle Voltaire Women’s Center - Haiti | |||||||
| Risk-adapted treatment of pediatric Burkitt Lymphoma in sub-Saharan Africa | Baylor College of Medicine, Texas Children’s Hospital, Houston, TX | Baylor College of Medicine Children’s Foundation – Uganda | |||||||
| Point-of-care diagnostics for lymphoma | Dana-Farber Cancer Institute, Brookline, MA | La Nacional Contra el Cancer (INCAN) – Guatemala | |||||||
| Implementation of Tanzania’s National Cancer Treatment Guidelines at Ocean Road Cancer Institute | University of San Francisco (UCSF) Foundation, San Francisco, CA | Ocean Road Cancer Institute – Tanzania | |||||||
| Advancing pharmacy care for cancer patients in South Asia | Vennue Foundation, Stamford, CT | Healthcare centers providing cancer care in Bangladesh and Nepal | |||||||
| Implementing multidisciplinary cervical cancer care in Nepal | American Society of Clinical Oncology (ASCO), Alexandria, VA | Bhaktapur Cancer Hospital – Nepal | |||||||
| Improve diagnosis and treatment of cancer in children, adolescents and young adults in Ghana | World Child Cancer, London, UK | Korle Bu Teaching Hospital – Ghana | |||||||
| Optimizing adherence to standard therapy delivery in non-metastatic breast cancer patients in Botswana | University of Pennsylvania, Philadelphia, PA | Princess Marina Hospital – Botswana | |||||||
| Long-distance learning platform (ONCOENSINO) | Brazilian Lymphoma and Leukemia Society (ABRALE), Sao Paulo, Brazil | ||||||||
“The programs we are supporting through Celgene Cancer Care Links address many important areas of cancer diagnosis and care,” said Joe Camardo, M.D., Senior Vice President, Global Health and Corporate Affairs Medical Strategy at Celgene. “For patients in resource-constrained nations like these, programs addressing this area fill a vital need in healthcare capacity.”
About Celgene Cancer Care Links™
Celgene Cancer Care Links is a grant program to support health care capacity initiatives that enhance patient cancer care in resource-constrained countries. Celgene Cancer Care Links is a demonstration of Celgene's commitment to improving the lives of patients worldwide.
The Celgene Cancer Care Links program is also featured in Access Accelerated, a group of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease treatment and care in low and middle-income countries. In addition to each company committing to do more with their individual programs, Access Accelerated also includes partnerships with the World Bank and the Union of International Cancer Control. Access Accelerated is part of the private sector’s commitment to achieving the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by 2030.
For more information on these programs, as well as Celgene’s Corporate Responsibility and Global Health efforts, please visit the following links:
http://www.celgene.com/responsibility/global-health/celgene-cancer-care-links/
http://www.AccessAccelerated.org
https://www.celgene.com/responsibility/global-health/
https://www.celgene.com/responsibility/
To read our latest Corporate Responsibility report, please visit https://media.celgene.com/content/uploads/Celgene-2018-CR-Report.pdf
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com . Follow Celgene on Social Media: @Celgene , Pinterest , LinkedIn , Facebook and YouTube .
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. Celgene undertakes no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in Celgene's Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005342/en/
Contact:
Celgene Corporation Investors: +1-908-673-9628 ir@celgene.com or Media: +1-908-673-2275 media@celgene.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom